Divincell
Develops peptide-nanoparticle RNA therapies for cancer and genetic diseases
Highlights
- New on EvolcAdded 2026-11-13
About Divincell
Divincell develops RNA therapies using modified RNA molecules and peptide-based nanoparticles designed to deliver treatments to targeted cells. Its programs include tumor-suppressor gene restoration, oncogene editing or suppression, and in vivo CAR-T therapy.
The company focuses on treatments for cancer, autoimmune diseases, and genetic diseases. Divincell SAS was founded in 2018 and is headquartered in Nîmes, France.
Product: Peptide-nanoparticle RNA therapeutics, including programs for tumor-suppressor restoration, oncogene suppression, and in vivo CAR-T.
Jobs at Divincell
Leadership
- Neil Desai · cofounder of Divincell SASSource: company website
- Gilles Divita · cofounder and CEO of DivinCell SAS (FR)Source: company website
More biotech & pharma companies
Dna Gensee
Plant DNA testing and R&D project services for industrial companies using plants or algae in their productsNew on EvolcDNA Script
Benchtop enzymatic DNA synthesis system for labs that need ready-to-use oligos in-house, overnightRemote-friendlyDomes Pharma
Develops, manufactures and markets medicines and care products for companion animal health and veterinary professionalsDoxanano
Develops radiation-activated nanoparticle drug delivery for patients with solid tumorsYoung companyNew on EvolcEdelris
Drug discovery research and chemistry services for pharmaceutical, biotech, cosmetic and crop-protection organizationsEffik
Women's health and intimate care products sold by a French pharmaceutical laboratory, founded in 1992 near Paris
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.